YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer

被引：0
|
作者：
Lei Wang
Quanren Wang
Piaopiao Xu
Li Fu
Yun Li
Haoyu Fu
Haitian Quan
Liguang Lou
机构：
[1] Chinese Academy of Sciences,Shanghai Institute of Materia Medica
来源：
British Journal of Cancer | 2020年 / 123卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1000 / 1011
页数：11
相关论文
共 50 条
  • [41] HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
    Sakai, Hitomi
    Tsurutani, Junji
    Iwasa, Tsutomu
    Komoike, Yoshifumi
    Sakai, Kazuko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    BREAST CANCER, 2018, 25 (05) : 605 - 613
  • [42] HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
    Hitomi Sakai
    Junji Tsurutani
    Tsutomu Iwasa
    Yoshifumi Komoike
    Kazuko Sakai
    Kazuto Nishio
    Kazuhiko Nakagawa
    Breast Cancer, 2018, 25 : 605 - 613
  • [43] Ado-trastuzumab emtansine (T-DM1) is effective against established HER2-positive breast cancer brain metastases in mice
    Askoxylakis, V.
    Ferraro, G.
    Kodack, D.
    Badeaux, M.
    Jain, R.
    CANCER RESEARCH, 2016, 76
  • [44] Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
    Montemurro, Filippo
    Ellis, Paul
    Anton, Antonio
    Wuerstlein, Rachel
    Delaloge, Suzette
    Bonneterre, Jacques
    Quenel-Tueux, Nathalie
    Linn, Sabine C.
    Irahara, Natsumi
    Donica, Margarita
    Lindegger, Nicolas
    Barrios, Carlos H.
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 92 - 102
  • [45] Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients
    Fabi, Alessandra
    Allegretti, Matteo
    Giordani, Elena
    Ferretti, Gianluigi
    Arpino, Grazia
    Zambelli, Alberto
    Omarini, Claudia
    Paris, Ida
    Botticelli, Andrea
    Bria, Emilio
    Palazzo, Antonella
    Gori, Stefania
    Cognetti, Francesco
    Giacomini, Patrizio
    CANCER RESEARCH, 2023, 83 (05)
  • [46] Cardiac safety of trastuzumab emtansine (T-DM1), a novel cancer drug linking trastuzumab to a chemotherapeutic agent for early-stage HER2-positive breast cancer
    Suter, T.
    Gianni, L.
    Krop, I.
    Xu, N.
    Smitt, M.
    Dang, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S101 - S101
  • [47] Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study
    Yardley, Denise Aysel
    Krop, Ian E.
    LoRusso, Patricia
    Robert, Nicholas J.
    Mayer, Musa
    Abidoye, Oyewale O.
    Lai, Catherine
    Yoo, Bongin
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [48] Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
    Burris, Howard A., III
    Tibbitts, Jay
    Holden, Scott N.
    Sliwkowski, Mark X.
    Phillips, Gail D. Lewis
    CLINICAL BREAST CANCER, 2011, 11 (05) : 275 - 282
  • [49] Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer
    Baron, Jessica M.
    Boster, Bonnie L.
    Barnett, Chad M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (02) : 132 - 142
  • [50] Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC)
    Jin, Jin
    Wang, Bei
    Gao, Yuying
    Samant, Meghan
    Li, Chunze
    Song, Chunyan
    Swain, Sandra M.
    Untch, Michael
    Girish, Sandhya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345